Cryptogenic Stroke and Patent Foramen Ovale.

Mojadidi, Mohammad K; Zaman, Muhammad O; Elgendy, Islam Y; Mahmoud, Ahmed N; Patel, Nimesh K; Agarwal, Nayan; Tobis, Jonathan M; Meier, Bernhard (2018). Cryptogenic Stroke and Patent Foramen Ovale. Journal of the American College of Cardiology, 71(9), pp. 1035-1043. Elsevier 10.1016/j.jacc.2017.12.059

Text Cryptogenic Stroke and Patent Foramen Ovale..pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (930kB) | Request a copy

Nearly one-half of patients with cryptogenic stroke have a patent foramen ovale (PFO). The dilemma of whether to close these PFOs percutaneously, in an effort to reduce the risk of recurrent paradoxical embolism, has been a matter of ongoing debate for more than a decade. Early randomized clinical trials failed to demonstrate a significant benefit of percutaneous PFO closure for secondary prevention of cryptogenic stroke in an intention-to-treat analysis. The long-term follow-up data from the RESPECT trial and 2 new randomized trials (CLOSE and REDUCE) have clarified these findings. They showed that with good patient selection, transcatheter PFO closure significantly reduces the risk of recurrent stroke compared with medical therapy in patients with cryptogenic stroke, with no increased risk of serious adverse events or influence on major bleeding.

Interest & Impact

Downloads

1 since deposited on 27 Feb 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item